MA50045A - Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci - Google Patents

Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci

Info

Publication number
MA50045A
MA50045A MA050045A MA50045A MA50045A MA 50045 A MA50045 A MA 50045A MA 050045 A MA050045 A MA 050045A MA 50045 A MA50045 A MA 50045A MA 50045 A MA50045 A MA 50045A
Authority
MA
Morocco
Prior art keywords
preparation
methods
same
spirocyclic compounds
spirocyclic
Prior art date
Application number
MA050045A
Other languages
English (en)
French (fr)
Inventor
Daniel J Buzard
Cheryl A Grice
Michael B Shaghafi
Olivia D Weber
Original Assignee
Lundbeck La Jolla Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck La Jolla Research Center Inc filed Critical Lundbeck La Jolla Research Center Inc
Publication of MA50045A publication Critical patent/MA50045A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050045A 2017-08-29 2018-08-28 Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci MA50045A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762551714P 2017-08-29 2017-08-29

Publications (1)

Publication Number Publication Date
MA50045A true MA50045A (fr) 2020-07-08

Family

ID=65526036

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050045A MA50045A (fr) 2017-08-29 2018-08-28 Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci

Country Status (24)

Country Link
US (1) US11161856B2 (enExample)
EP (1) EP3675848B1 (enExample)
JP (1) JP7177825B2 (enExample)
KR (1) KR20200046053A (enExample)
CN (1) CN111032034B (enExample)
AU (1) AU2018326497A1 (enExample)
BR (1) BR112020003946A2 (enExample)
CA (1) CA3072926A1 (enExample)
CL (1) CL2020000463A1 (enExample)
CO (1) CO2020001715A2 (enExample)
CR (1) CR20200088A (enExample)
DO (1) DOP2020000040A (enExample)
EA (1) EA202090296A1 (enExample)
EC (1) ECSP20013332A (enExample)
ES (1) ES2914363T3 (enExample)
IL (1) IL272578A (enExample)
JO (1) JOP20200022A1 (enExample)
MA (1) MA50045A (enExample)
MX (1) MX2020002254A (enExample)
PE (1) PE20200665A1 (enExample)
PH (1) PH12020500371A1 (enExample)
RU (1) RU2020107039A (enExample)
SG (1) SG11202000984YA (enExample)
WO (1) WO2019046330A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
CN109996790B (zh) 2016-09-19 2023-05-16 H.隆德贝克有限公司 哌嗪氨基甲酸酯及其制备和使用方法
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
RU2020107039A (ru) 2017-08-29 2021-09-30 Лундбекк Ла-Хойя Рисерч Сентер, Инк. Спироциклические соединения и способы их получения и применения
UA126685C2 (uk) 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
MA52635A (fr) * 2018-05-15 2021-03-24 H Lundbeck As Inhibiteurs de magl
CN111505410B (zh) * 2020-04-02 2022-07-29 矽力杰半导体技术(杭州)有限公司 调光模式检测电路、方法和无调光检测电路及照明系统
WO2021214550A1 (en) 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商H 朗德貝克公司 Magl抑制劑
KR20230142745A (ko) 2021-01-29 2023-10-11 세딜라 테라퓨틱스, 인크. Cdk2 억제제 및 그의 사용 방법
TW202317560A (zh) 2021-06-26 2023-05-01 美商賽迪拉治療股份有限公司 Cdk2抑制劑及其使用方法
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)
WO2023213854A1 (en) * 2022-05-04 2023-11-09 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070523A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
JPWO2008023720A1 (ja) * 2006-08-23 2010-01-14 アステラス製薬株式会社 ウレア化合物又はその塩
US20110071180A1 (en) 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
WO2011109277A1 (en) 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
PL2900669T3 (pl) 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
US9828379B2 (en) 2013-07-03 2017-11-28 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016149401A2 (en) * 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
MX375424B (es) 2015-07-31 2025-03-06 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl
US10519134B2 (en) * 2015-11-20 2019-12-31 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
UA126685C2 (uk) 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
RU2020107039A (ru) 2017-08-29 2021-09-30 Лундбекк Ла-Хойя Рисерч Сентер, Инк. Спироциклические соединения и способы их получения и применения

Also Published As

Publication number Publication date
MX2020002254A (es) 2020-07-20
CR20200088A (es) 2020-04-08
PH12020500371A1 (en) 2020-12-07
EA202090296A1 (ru) 2020-08-03
PE20200665A1 (es) 2020-06-11
KR20200046053A (ko) 2020-05-06
US20210214375A1 (en) 2021-07-15
JOP20200022A1 (ar) 2020-02-02
SG11202000984YA (en) 2020-03-30
RU2020107039A (ru) 2021-09-30
US11161856B2 (en) 2021-11-02
CL2020000463A1 (es) 2020-07-10
JP7177825B2 (ja) 2022-11-24
AU2018326497A1 (en) 2020-02-20
CN111032034A (zh) 2020-04-17
EP3675848A1 (en) 2020-07-08
EP3675848A4 (en) 2021-03-10
JP2020532547A (ja) 2020-11-12
DOP2020000040A (es) 2020-08-31
CO2020001715A2 (es) 2020-02-28
IL272578A (en) 2020-03-31
ES2914363T3 (es) 2022-06-09
CN111032034B (zh) 2023-05-02
WO2019046330A1 (en) 2019-03-07
BR112020003946A2 (pt) 2020-09-08
EP3675848B1 (en) 2022-03-23
ECSP20013332A (es) 2020-04-22
CA3072926A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
EP3675848A4 (en) SPIROCYCLUS COMPOUNDS AND METHOD OF MANUFACTURING AND USING THEREOF
MA50041A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3370715A4 (en) CHIMERIC COMPOUNDS PROVIDED AGAINST PROTEOLYSIS AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP3455226A4 (en) SPIROCYCLIC COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP3704239A4 (en) CASZ COMPOSITIONS AND METHOD OF USE
EP3463665A4 (en) COVALENTLY MODIFIED SURFACES, KITS AND METHODS OF PRODUCTION AND USE
EP3504213A4 (en) AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHOD FOR USE THEREOF
EP3429635A4 (en) ANTI-CRISPR COMPOUNDS AND METHOD OF USE
EP3504251A4 (en) NETWORK POLYMERS AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP3645742A4 (en) Anti-ror1 antibodies and methods of making and using thereof
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
EP3645049A4 (en) MULTISPECIFIC ANTIBODIES AND THE METHOD OF MANUFACTURING AND USING THEREOF
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
MA52492A (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA49752A (fr) Procédés de préparation de composés de pyrrolidine
MA54252A (fr) Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
EP3359164A4 (en) COMPOUNDS AND METHOD FOR MODULATING ANGIOTENSINOGENEXPRESSION
EP3271352A4 (en) PIPERAZINE CARBAMATES AND PROCESS FOR THE PREPARATION AND USE THEREOF
MA44611A (fr) Compositions de composés hydrophobes cristallisés et leurs procédés de préparation et d'utilisation
MA49560A (fr) Composés cétoniques bicycliques et leurs procédés d'utilisation
EP3526205A4 (en) THERAPEUTIC CONNECTIONS AND METHOD FOR USE THEREOF
EP3429754A4 (en) SAMPLE PREPARATION CARTRIDGES AND METHOD OF USE THEREOF
EP3468555A4 (en) ANTIMICROBIAL CONNECTIONS AND METHOD FOR USE THEREOF
EP3349755A4 (en) NICOTINE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF
EP3307254A4 (en) MITO-HONOKIOL COMPOUNDS AND METHOD FOR SYNTHESIS AND USE THEREOF